PODD Insulet (PODD) Insider Trading, Ownership & Congress Trades
Medical Devices · Surgical & medical instruments & apparatus · CIK 0001145197
Cluster · 3 insidersC-suite buying · 1Congress · 1
Funds added, last quarter
422
13F, latest reported quarter
What the filings say about PODD
Insiders, 180 days
+$1.0M net bought
3 buyers · 1 seller · 0% of sales under a 10b5-1 plan
Congress, 1 year
1 bought · 1 sold
Latest: sale, 2026-09-18
Insulet insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, INSULET CORP insiders bought a net $1.0M of stock across 77 Form 4 purchases and sales, with 3 insiders buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Feb 20, 2026.
- The trade is 4.6% of the 23,731 shares held after it.
- No other insider bought within 30 days.
- 422 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO McEvoy Ashley bought about $162.2K of PODD on Aug 21, 2026; 422 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on Dec 5, 2025.
- The trade is 30.9% of the 9,041 shares held after it.
- 1 other insider bought within 30 days.
- 422 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director STONESIFER TIMOTHY C. bought about $400.4K of PODD on Jun 3, 2026; 1 other insider bought within 30 days and 422 funds added in the latest 13F quarter.Context
- 5 earlier Form 4 trades (code P or S) here by this insider (5 sales), the last on Jun 9, 2025.
- The trade is 9.7% of the 4,329 shares held after it.
- No other insider sold within 30 days.
- 422 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director BORIO LUCIANA sold about $59.9K of PODD on Jun 3, 2026; 422 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 33.3% of the 10,352 shares held after it.
- 1 other insider bought within 30 days.
- 422 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director WEATHERMAN ELIZABETH H bought about $497.5K of PODD on Jun 3, 2026; 1 other insider bought within 30 days and 422 funds added in the latest 13F quarter.Context
- 1 earlier Form 4 trade (code P or S) here by this insider (1 buy), the last on May 23, 2023.
- The trade is 11.6% of the 17,483 shares held after it.
- 1 other insider bought within 30 days.
- 422 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director MINOGUE MICHAEL R bought about $499.8K of PODD on Feb 25, 2026; 1 other insider bought within 30 days and 422 funds added in the latest 13F quarter.77 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net +$1.0M over 180 days
+$162.2K over 90 days
more than 92% of Medical Devices
Congress
1 member bought in the last year
the lowest in Medical Devices
Funds
422 funds bought in last quarter
more than 93% of Medical Devices
Revenue
+30.7% year over year
more than 80% of Medical Devices
Margin
9.1% net margin
more than 81% of Medical Devices
Buybacks
$300.0M repurchased, FY to 2026-06-30
more than 78% of Medical Devices
Short interest
7.8% of the float short (float per yahoo 2026-10-26) · 3.9 days to cover · settled 2026-09-30
more than 80% of Medical Devices
The situation: each line is one rule over one dataset
3 insiders independently bought a net $1.0M while the stock fell 21% over six months, with no planned sales queued.
What changed in the last 30 days
Oct 12Rep. Gilbert Cisneros sold $1.0K to $15K, disclosed 24 days after the trade
Why it matters
House members report a bracket, not an exact amount, and have 45 days to do it; the trade is weeks old when it becomes public.
Watch PODD
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-53.9%12M
Insider buyInsider sell
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns PODD: institutional holders (13F)
13F holdings, latest reported quarter
6,690,192 sh
$1.0B
4,525,333 sh
$689.0M
3,197,555 sh
$486.8M
3,075,932 sh
$468.3M
2,455,135 sh
$373.8M
Congress trades in PODD
STOCK Act disclosures, US House only, filed up to 45 days after the trade
Sold 2026-09-18 · disclosed 24 days later
$1,001 - $15,000
Bought 2026-08-18 · disclosed 23 days later
$1,001 - $15,000
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
PODD planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
PODD mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
Global X HealthTech ETF
$846.9K position · as of 2026-05-31
3.4%
T. Rowe Price Health Care ETF
$548.3K position · as of 2026-06-30
2.4%
ICON HEALTH AND INFORMATION TECHNOLOGY FUND
$2.1M position · as of 2026-06-30
2.2%
Harbor Health Care ETF
$864.1K position · as of 2026-07-31
2.1%
AMG Frontier Small Cap Growth Fund
$1.9M position · as of 2026-07-31
2.0%
Nuveen Quant Mid Cap Growth Fund
$12.6M position · as of 2026-07-31
2.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Executive pay vs shareholder return · James Hollingshead
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2023
$12.4M
$12.8M
$2.8M
+27%
+6%
2022
$10.8M
$16.1M
$3.4M
+72%
-0%
2021
$0
$0
$2.6M
+55%
+25%
2020
$0
$0
$2.4M
+49%
+30%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
3 insiders reported buying shares.
The record shows a net $1.0M bought by insiders over 180 days, 422 funds added last quarter, 1 House member(s) bought in 12 months, disclosed weeks after the trade. Each figure is a federal filing, dated the day it went public.
PODD financials
Revenue growth
+30.7%
XBRL, annual
Net margin
9.1%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$3.1B
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM PODD
| FY Dec 2025 | $2.7B |
| FY Dec 2024 | $2.1B |
| FY Dec 2023 | $1.7B |
| FY Dec 2022 | $1.3B |
| FY Dec 2021 | $1.1B |
| Jun 2026 | $801.7M |
| Mar 2026 | $761.7M |
| Dec 2025 | $783.8M |
| Sep 2025 | $706.3M |
| Jun 2025 | $649.1M |
| Mar 2025 | $569.0M |
| Dec 2024 | $597.5M |
| Sep 2024 | $543.9M |
At each fiscal year end
Single quarter
Net margin, TTM
+12.3%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM PODD
| FY Dec 2025 | +9.1% |
| FY Dec 2024 | +20.2% |
| FY Dec 2023 | +12.2% |
| FY Dec 2022 | +0.4% |
| FY Dec 2021 | +1.5% |
| Jun 2026 | +11.8% |
| Mar 2026 | +12.0% |
| Dec 2025 | +13.0% |
| Sep 2025 | +12.4% |
| Jun 2025 | +3.5% |
| Mar 2025 | +6.2% |
| Dec 2024 | +16.9% |
| Sep 2024 | +14.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$293.7M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM PODD
| FY Dec 2025 | $377.7M |
| FY Dec 2024 | $305.3M |
| FY Dec 2023 | $70.1M |
| FY Dec 2022 | -$3.9M |
| FY Dec 2021 | -$180.0M |
| Jun 2026 | $55.9M |
| Mar 2026 | $89.5M |
| Dec 2025 | $48.2M |
| Sep 2025 | $100.1M |
| Jun 2025 | $177.9M |
| Mar 2025 | $51.5M |
| Dec 2024 | $93.9M |
| Sep 2024 | $81.6M |
At each fiscal year end
Single quarter
Debt to equity
0.67x
long-term 2026-06-30 plus current 2026-06-30; equity 2026-06-30
Debt to equity PODD
| FY Dec 2025 | 0.63x |
| FY Dec 2024 | 1.14x |
| FY Dec 2023 | 1.93x |
| FY Dec 2022 | 2.94x |
| FY Dec 2021 | 2.29x |
| Jun 2026 | 0.67x |
| Mar 2026 | 0.73x |
| Dec 2025 | 0.63x |
| Sep 2025 | 0.73x |
| Jun 2025 | 0.96x |
| Mar 2025 | 1.27x |
| Dec 2024 | 1.14x |
| Sep 2024 | 1.25x |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.54x
TTM operating cash flow over long-term 2026-06-30 plus current 2026-06-30
Cash flow to debt PODD
| FY Dec 2025 | 0.60x |
| FY Dec 2024 | 0.31x |
| FY Dec 2023 | 0.10x |
| FY Dec 2022 | 0.08x |
| FY Dec 2021 | -0.05x |
| Jun 2026 | 0.54x |
| Mar 2026 | 0.65x |
| Dec 2025 | 0.60x |
| Sep 2025 | 0.53x |
| Jun 2025 | 0.37x |
| Mar 2025 | 0.24x |
| Dec 2024 | 0.31x |
| Sep 2024 | 0.23x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
+26.0%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity PODD
| FY Dec 2025 | +18.1% |
| FY Dec 2024 | +43.0% |
| FY Dec 2023 | +34.1% |
| FY Dec 2022 | +0.9% |
| FY Dec 2021 | +2.9% |
| Jun 2026 | +26.0% |
| Mar 2026 | +23.0% |
| Dec 2025 | +18.1% |
| Sep 2025 | +19.7% |
| Jun 2025 | +19.2% |
| Mar 2025 | +37.9% |
| Dec 2024 | +43.0% |
| Sep 2024 | +48.8% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
+11.3%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets PODD
| FY Dec 2025 | +7.9% |
| FY Dec 2024 | +14.7% |
| FY Dec 2023 | +8.5% |
| FY Dec 2022 | +0.2% |
| FY Dec 2021 | +0.9% |
| Jun 2026 | +11.3% |
| Mar 2026 | +9.3% |
| Dec 2025 | +7.9% |
| Sep 2025 | +8.1% |
| Jun 2025 | +7.4% |
| Mar 2025 | +13.1% |
| Dec 2024 | +14.7% |
| Sep 2024 | +15.3% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
+25.4%
operating income after a 24.1% effective tax rate, over long-term 2026-06-30 plus current 2026-06-30 plus average of 2025-06-30 and 2026-06-30 minus cash
Return on invested capital PODD
| FY Dec 2025 | +23.6% |
| FY Dec 2024 | n/a |
| FY Dec 2023 | +18.0% |
| FY Dec 2022 | n/a |
| FY Dec 2021 | +10.3% |
| Jun 2026 | +25.4% |
| Mar 2026 | +26.8% |
| Dec 2025 | +23.6% |
| Sep 2025 | +24.4% |
| Jun 2025 | +19.9% |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+21.1%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed PODD
| FY Dec 2025 | +18.7% |
| FY Dec 2024 | +13.2% |
| FY Dec 2023 | +10.9% |
| FY Dec 2022 | +2.0% |
| FY Dec 2021 | +7.2% |
| Jun 2026 | +21.1% |
| Mar 2026 | +19.2% |
| Dec 2025 | +18.7% |
| Sep 2025 | +17.8% |
| Jun 2025 | +16.8% |
| Mar 2025 | +13.1% |
| Dec 2024 | +13.2% |
| Sep 2024 | +13.5% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
27.95x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
P/E, trailing PODD
| FY Dec 2025 | 81.44x |
| FY Dec 2024 | 45.17x |
| FY Dec 2023 | 73.80x |
| FY Dec 2022 | 4,205.57x |
| FY Dec 2021 | 1,156.83x |
| Jun 2026 | 28.51x |
| Mar 2026 | 48.91x |
| Dec 2025 | 81.44x |
| Sep 2025 | 89.75x |
| Jun 2025 | 95.79x |
| Mar 2025 | 47.32x |
| Dec 2024 | 45.17x |
| Sep 2024 | 39.65x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$10.4B
market value at close 2026-10-26 on 2026-07-29 shares, plus long-term 2026-06-30 plus current 2026-06-30, minus cash 2021-09-30
Enterprise value PODD
| FY Dec 2025 | $20.1B |
| FY Dec 2024 | $18.8B |
| FY Dec 2023 | $15.7B |
| FY Dec 2022 | $21.0B |
| FY Dec 2021 | $18.8B |
| Jun 2026 | $10.6B |
| Mar 2026 | $14.9B |
| Dec 2025 | $20.1B |
| Sep 2025 | $21.9B |
| Jun 2025 | $22.7B |
| Mar 2025 | $19.3B |
| Dec 2024 | $18.8B |
| Sep 2024 | $16.9B |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+2.8%
TTM free cash flow over market value at close 2026-10-26
FCF yield PODD
| FY Dec 2025 | +1.9% |
| FY Dec 2024 | +1.7% |
| FY Dec 2023 | +0.5% |
| FY Dec 2022 | -0.0% |
| FY Dec 2021 | -1.0% |
| Jun 2026 | +2.8% |
| Mar 2026 | +2.8% |
| Dec 2025 | +1.9% |
| Sep 2025 | +1.9% |
| Jun 2025 | +1.8% |
| Mar 2025 | +1.6% |
| Dec 2024 | +1.7% |
| Sep 2024 | +1.4% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
0.45x
P/E over trailing EPS growth of 63%: four quarters to 2026-06-30 against the four to 2025-06-30
PEG, trailing PODD
| FY Dec 2025 | n/a |
| FY Dec 2024 | 0.47x |
| FY Dec 2023 | 0.02x |
| FY Dec 2022 | n/a |
| FY Dec 2021 | 8.90x |
| Jun 2026 | 0.45x |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | 0.71x |
| Dec 2024 | 0.47x |
| Sep 2024 | 0.16x |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $2.7B | $2.1B | $1.7B | $1.3B |
| Gross profit | $1.9B | $1.4B | $1.2B | $805.6M |
| Operating income | $473.8M | $308.9M | $220.1M | $37.6M |
| Net income | $247.1M | $418.3M | $206.3M | $4.6M |
| EPS (diluted) | 3.48 | 5.78 | 2.94 | 0.07 |
| Operating cash flow | $569.3M | $430.2M | $145.7M | $119.0M |
| Long-term debt | $930.8M | $1.3B | $1.4B | $1.4B |
| Buybacks | $59.6M | $0 | $0 | n/a |
SEC XBRL, fiscal years, as known on 2026-10-28
PODD Stock Sonar score 6/7 axes
Find similar shapesComparePODD ranks highest on profitability (92nd percentile) and insider conviction (88th), and lowest on risk and compliance (24th), among Medical Devices peers.
6 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
PODD filings, in plain words
Are Insulet insiders buying or selling PODD?
In the 180 days to 2026-10-28, Insulet insiders were net buyers, a net $1.0M: $1.1M of purchases and $59.9K of sales reported on Form 4, by 3 buyers and 1 seller.
Have members of Congress traded PODD?
Yes. In the year to 2026-10-28, 1 House member disclosed buying PODD and 1 House member disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2026-09-18.
Read the full summary
In the 180 days to 2026-10-28, Insulet insiders were net buyers of PODD, a net $1.0M across purchases and sales reported on Form 4 by 3 buyers and 1 seller. Purchases outweighed sales more than tenfold by value. 3 insiders reported purchases in that window. In the year to 2026-10-28, 1 member of Congress disclosed buying PODD and 1 member disclosed selling it; the latest on record is a sale by Gilbert Cisneros dated 2026-09-18. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
